{"meta":{"exportedAt":"2026-10-17T08:15:06.357Z","formatVersion":2,"selection":{"q":"thesis","system":"","harm":"","context":"","country":"","role":"","relation":"","evidence":"","year":"2025","response":"","severity":"","verification":"","view":"incidents","sort":"added"},"totalIncidents":2,"coverage":{"cases":2,"countries":1,"languages":2,"unknownLocation":1,"locationPending":0,"unknownLanguage":0,"unknownDate":0,"lawsuits":1,"regulatory":0,"minors":0,"coreRelations":2,"contextualRelations":0,"mixedRelations":0,"unknownRelations":0,"relationPending":0,"relationUnknown":0},"countingNote":"Distinct public cases in this selection. People counts apply within individual cases only; cross-case person overlap has not been resolved. No population incidence estimate.","affectedCountNote":"Interpret person counts with affectedCountStatus and the reported effects. Unquantified zeros are placeholders, not a measured zero.","source":"AI incidents","publisher":"NOPE","url":"https://nope.net/incidents","license":"CC BY 4.0"},"incidents":[{"id":"2025-case-report-deepseek-guided-fever-self-diagnosis-unsupervised-colchicine-liver-enzymes","caseFacts":{"claims":[{"id":"c1","status":"reported","evidence":[{"locator":"'Since early childhood, he had experienced recurrent inflammatory attacks characterized by fever, severe migratory abdominal pain, arthralgia involving the knees, feet and hips, lower-limb myalgia, and intermittent erythematous skin lesions.'; 'Despite almost 3 decades of symptoms, extensive investigations, including contrast-enhanced abdominal CT and MRI, gastroscopy, colonoscopy, and urological assessment, failed to establish a diagnosis.'","relation":"supports","source_id":"s1"}],"assertion":"A man in his thirties had had recurrent febrile attacks since early childhood, and nearly three decades of investigations had produced no diagnosis.","causal_attribution":"The patient's history as taken and written up by the treating clinicians."},{"id":"c2","status":"reported","evidence":[{"locator":"'the patient began a dialogue with the publicly available LLM (DeepSeek-R1-0528) on June 28, 2025.'; 'FMF was presented as the leading diagnosis'; 'Although the model continued to recommend rheumatological assessment and MEFV testing, its language became increasingly confident, at times describing the presentation as classic or highly suggestive of FMF. It also repeatedly discussed a diagnostic trial of colchicine and provided specific dosing suggestions before specialist assessment.'; 'it explicitly advised that colchicine should only be initiated with specialist approval and appropriate laboratory monitoring.'","relation":"supports","source_id":"s1"}],"assertion":"In a dialogue with DeepSeek-R1-0528 begun on 28 June 2025, the model came to present familial Mediterranean fever as the leading diagnosis in increasingly confident language and repeatedly discussed a diagnostic trial of colchicine with specific dosing before specialist assessment, while also recommending specialist evaluation and, in its final reply on his other medication, advising colchicine only with specialist approval and monitoring.","causal_attribution":"The authors' description of the conversation, which they include as a supplement that was not inspected here."},{"id":"c3","status":"reported","evidence":[{"locator":"'Motivated by the LLM-generated diagnostic hypothesis, the patient independently obtained commercial genetic MEFV testing at Alfa Labs, Egypt, which identified 2 pathogenic MEFV variants'; 'Before specialist assessment, he obtained colchicine himself from a pharmacy in Egypt and initiated treatment at a dose of 0.5 mg twice daily without prior specialist supervision.'; 'the patient nevertheless translated the generated diagnostic hypothesis into autonomous genetic testing and self-medication.'","relation":"supports","source_id":"s1"}],"assertion":"Motivated by the model's hypothesis, he arranged commercial genetic testing in Egypt, which found two pathogenic MEFV variants, and obtained colchicine from a pharmacy in Egypt, starting 0.5 mg twice daily without specialist supervision.","causal_attribution":"The patient's account as reported by the treating clinicians; the authors state the motivation."},{"id":"c4","status":"reported","evidence":[{"locator":"'Following colchicine initiation, recurrent febrile attacks ceased completely for the first time since childhood. However, alanine aminotransferase increased to 160 U/L. In view of the elevated liver enzymes, colchicine was temporarily discontinued, and liver enzyme levels were monitored closely by the primary care physician.'; 'colchicine treatment was resumed at a dose of 0.5 mg/d under close supervision.'","relation":"supports","source_id":"s1"}],"assertion":"After he started colchicine his febrile attacks ceased, but his alanine aminotransferase rose to 160 U/L; colchicine was temporarily discontinued under primary-care monitoring and later resumed at 0.5 mg daily under close supervision.","causal_attribution":"Clinical course reported by the authors; the liver tests were monitored by his primary care physician."},{"id":"c5","status":"documented","evidence":[{"locator":"'Based on the characteristic lifelong clinical phenotype, Mediterranean ancestry, suggestive family history, identification of 2 pathogenic MEFV variants, and clinical response to colchicine, the diagnosis of FMF was confirmed'; 'The patient has remained free of attacks with regular clinical and laboratory follow-up.'","relation":"supports","source_id":"s1"}],"assertion":"At the authors' clinic in February 2026 the diagnosis of familial Mediterranean fever was confirmed, and he has remained free of attacks under follow-up.","causal_attribution":"The treating specialists' own diagnostic finding, directly recorded in their report."},{"id":"c6","status":"reported","evidence":[{"locator":"'although the model consistently recommended specialist evaluation before treatment initiation, the patient nevertheless translated the generated diagnostic hypothesis into autonomous genetic testing and self-medication. The subsequent elevation of liver enzymes illustrates that even clinically accurate diagnostic suggestions may inadvertently encourage harmful behavior if patients perceive the model as sufficiently authoritative.'; 'generic recommendations to seek specialist advice may not sufficiently mitigate risk when they are accompanied by confident diagnostic language and actionable treatment instructions'","relation":"supports","source_id":"s1"}],"assertion":"The authors write that, although the model consistently recommended specialist evaluation, the patient turned its hypothesis into autonomous testing and self-medication, that the liver-enzyme rise shows accurate suggestions can encourage harmful behaviour when the model seems authoritative, and that generic advice to see a specialist may not mitigate risk alongside confident language and actionable treatment instructions.","causal_attribution":"The authors' interpretation of the model's role; the model also advised specialist supervision, so causation is alleged."}],"effects":[{"label":"liver enzyme rise during colchicine self-treatment started without specialist supervision, so the drug was paused","claim_id":"c4","direction":"negative"},{"label":"attacks stopped and a long-missed diagnosis was later confirmed by specialists","claim_id":"c5","direction":"positive"}],"sources":[{"id":"s1","url":"https://www.ebi.ac.uk/europepmc/webservices/rest/PMC13651492/fullTextXML","kind":"clinical_case_report","access":"read","language":"en","translation_note":"Full text of the peer-reviewed case report read as Europe PMC fullTextXML for PMC13651492 (HTTP 200) on 2026-10-12: abstract, case description, discussion, consent and AI-use declarations. Written by the treating clinicians. The supplementary DeepSeek conversation was not inspected.","independence_group":"eular-rheumatol-open-pauz-2026-case-report"}],"version":1,"ai_roles":["own_use"],"contexts":["health"],"unknowns":["What DeepSeek replied in each turn; the supplementary transcript was not inspected.","Where the patient held the dialogue and where his liver enzymes were monitored.","Whether the liver-enzyme rise had any cause other than colchicine, including the other long-term medication he was taking; the report does not discuss alternatives."],"geography":{"basis":"The report says the patient obtained the genetic test at a laboratory in Egypt and the colchicine from a pharmacy in Egypt (EG). It does not say where he held the DeepSeek dialogue or where his liver enzymes were monitored. He later presented to the authors' clinic in Hamburg; that confirmation visit is not used as the event location, and birthplace is not used as residence. No court proceeding is reported.","court_countries":[],"event_countries":["EG"],"affected_person_countries":[]},"publication":{"basis":"Core case (communicated_with): the treating clinicians report that a DeepSeek dialogue presented a rare fever syndrome as the leading diagnosis with specific colchicine dosing, and that the patient then self-medicated without supervision and developed a liver-enzyme rise that led to a pause in treatment. The account is mixed: the model also advised specialist supervision and the patient's attacks stopped, so causation is alleged and severity low.","reviewed_on":"2026-10-12"},"ai_involvement":{"basis":"The treating clinicians, who include the full conversation as a supplement, report that DeepSeek-R1-0528 progressively presented familial Mediterranean fever as the leading diagnosis in increasingly confident language and repeatedly discussed a diagnostic colchicine trial with specific dosing before specialist assessment, and that the patient, motivated by that hypothesis, arranged genetic testing and started colchicine unsupervised, after which his liver enzymes rose. They also report that the model repeatedly advised specialist supervision.","status":"reported"},"person_relations":["communicated_with"]},"name":"Case report: man self-treated with colchicine after a DeepSeek dialogue pointed to a rare fever syndrome; liver enzymes rose before specialist review","summary":"Clinicians at the University Medical Center Hamburg-Eppendorf report in EULAR Rheumatology Open (published 29 September 2026) a man in his thirties with nearly three decades of unexplained febrile attacks who, in a dialogue with DeepSeek begun on 28 June 2025, saw the model's differential narrow to familial Mediterranean fever (FMF). The authors write that the model repeatedly recommended specialist assessment but also discussed a diagnostic trial of colchicine with specific dosing. Motivated by the hypothesis, he arranged commercial genetic testing and obtained colchicine from a pharmacy in Egypt, starting it without specialist supervision. His attacks stopped, but his alanine aminotransferase rose to 160 U/L and colchicine was paused and later resumed at a lower dose. FMF was confirmed when he presented to the clinic in February 2026. The authors write that the case illustrates how patient-facing models may facilitate recognition of rare autoinflammatory diseases, and that confident diagnostic language combined with actionable treatment advice may also encourage unsupervised testing and self-medication.","incidentDate":"2025-06-28","incidentKind":"single_event","incidentDatePrecision":"day","exposurePattern":"single_interaction","reportedDate":"2026-09-29","aiSystem":"DeepSeek (DeepSeek-R1-0528, the publicly available model), used by the patient in an iterative diagnostic dialogue (case report by the treating clinicians)","aiProduct":"DeepSeek","aiCompany":"DeepSeek","severity":"low","verificationStatus":"credible","harmCategories":[],"harmOutcomes":["medical_deterioration"],"harmOutcomeSummary":"The treating clinicians report that after the DeepSeek dialogue the patient started colchicine without specialist supervision and his alanine aminotransferase rose to 160 U/L, so the drug was paused and resumed at a lower dose; they also report that his attacks stopped and that the diagnosis was later confirmed.","frameworkFacets":[],"causationStatus":"alleged","participantUsersAffectedMin":1,"otherPeopleHarmedMin":0,"affectedCountStatus":"exact","affectedCountEvidence":"One patient, the subject of the case report. Exact 1.","victimAgeRange":"adult","platformType":"chatbot","outcomeType":"media_coverage","outcomeStatus":"unknown","primarySourceUrl":"https://www.ebi.ac.uk/europepmc/webservices/rest/PMC13651492/fullTextXML","primarySourceLabel":"EULAR Rheumatology Open, 29 September 2026: Pauz et al., LLM-supported self-diagnosis and self-treatment of FMF (case report, Europe PMC full text)","firstPublishedAt":"2026-10-12T03:14:06.074846+00:00","updatedAt":"2026-10-12T03:14:06.074846+00:00","scopeVersion":"facts-v3","tags":["deepseek","case-report","self-medication","self-diagnosis","colchicine","rare-disease","communicated-with"]},{"id":"2025-shanghai-voice-actor-ai-synthesised-voice-company-promotion-appeal-ruling","caseFacts":{"claims":[{"id":"c1","status":"reported","evidence":[{"locator":"'2026年9月29日，上海市第一中级人民法院依法审结上海首例人工智能合成语音引发的自然人声音权益保护纠纷案件，判决平台运营方构成声音侵权，赔偿权利人经济损失5万元'","relation":"supports","source_id":"s1"},{"locator":"'上海市第一中级人民法院依法判决：驳回上诉，维持原判'","relation":"supports","source_id":"s1"},{"locator":"'驳回上诉，维持原判'","relation":"supports","source_id":"s2"},{"locator":"'经上海市第一中级人民法院二审，于2026年9月29日驳回上诉，维持原判'","relation":"supports","source_id":"s3"}],"assertion":"On 29 September 2026 the Shanghai No. 1 Intermediate People's Court concluded a voice-rights case arising from AI-synthesised speech, described as the first in Shanghai, holding that the platform operator infringed and must pay 50,000 yuan for economic loss; the appeals were dismissed and the first-instance judgment upheld.","causal_attribution":"Court outcome as relayed by outlets citing the court; the judgment was not inspected."},{"id":"c2","status":"reported","evidence":[{"locator":"'2025年1月'; '从好友处了解到'; 'A公司在其互联网推广拉新活动中疑似使用了'; '该活动使用的自己声音疑似AI合成，于是对相关音频进行了公证以固定证据'","relation":"supports","source_id":"s1"}],"assertion":"In January 2025 the voice actor learned from a friend that Company A appeared to be using the voice actor's voice in an online user-acquisition promotion, judged the audio to be AI-synthesised and had it notarised before suing.","causal_attribution":"The claimant's case as summarised in the court account."},{"id":"c3","status":"reported","evidence":[{"locator":"'其从未与A公司进行过合作和任何授权，A公司擅自使用其声音构成侵权，遂要求A公司停止侵权并赔偿经济损失30万元'","relation":"supports","source_id":"s1"}],"assertion":"The voice actor said there had been no cooperation with or authorisation of Company A and asked the court to stop the use and award 300,000 yuan.","causal_attribution":"The claimant's position as summarised in the court account."},{"id":"c4","status":"reported","evidence":[{"locator":"'A公司辩称，案涉音频确为该公司开发的AI生成，但具体的来源和投喂的素材因前员工离职无法确认'","relation":"supports","source_id":"s1"}],"assertion":"Company A said the audio was generated by AI the company had developed, but that its source and the material fed to the system could not be confirmed because a former employee had left.","causal_attribution":"The company's defence as summarised in the court account; the company denied using the voice actor's voice."},{"id":"c5","status":"reported","evidence":[{"locator":"'在28个共振峰声学指标中'; '有24个偏离度小于10%，其中16个小于5.36%，两者较为相似及高度相似的部分达到90%'","relation":"supports","source_id":"s1"}],"assertion":"A forensic comparison found that 24 of 28 formant indicators deviated by less than 10 percent and that the parts rated fairly or highly similar reached 90 percent.","causal_attribution":"Forensic opinion as summarised in the court account."},{"id":"c6","status":"reported","evidence":[{"locator":"'A公司的行为构成人工智能生成声音侵权'; '赔偿5万元'; '双方均不服一审判决，提起上诉'","relation":"supports","source_id":"s1"},{"locator":"'并向长宁区人民法院提出起诉'","relation":"supports","source_id":"s3"}],"assertion":"The first-instance court awarded 50,000 yuan and both sides appealed; the Legal Daily report carried on Sina Finance says the claim was filed in the Changning District People's Court.","causal_attribution":"Procedural history as relayed from the court account."},{"id":"c7","status":"reported","evidence":[{"locator":"'未经自然人同意，使用自然人的声音作为训练语料，模仿该自然人的音色、语调和发音风格等生成能够识别该自然人的合成人声，应当认定侵害自然人声音权益'; '应承担举证不能的不利后果'","relation":"supports","source_id":"s1"}],"assertion":"The appeal court held that using a person's voice as training material without consent to generate an identifiable synthetic voice infringes that person's voice rights, and that Company A bore the consequence of failing to prove the lawful source of its material.","causal_attribution":"The appeal court's reasoning as relayed; it rests on a presumption from similarity and access, because the company did not produce its training records."},{"id":"c8","status":"reported","evidence":[{"locator":"'涉案语音上架持续时间较短，属流程播报提示音效'","relation":"supports","source_id":"s1"}],"assertion":"The appeal court noted that the audio was online for a short time and was a process prompt sound in the promotion.","causal_attribution":"The appeal court's reasoning on the amount, as relayed."}],"effects":[{"label":"courts reported to have found a voice actor's voice identifiable in AI-synthesised audio used without consent in a company promotion","claim_id":"c1","direction":"negative"}],"sources":[{"id":"s1","url":"https://news.ifeng.com/c/8woTv1MjTRx","kind":"news_report","access":"read","language":"zh","translation_note":"The Paper's article as carried on ifeng, read in the original Chinese on 2026-10-05 (HTTP 200). English renderings in this record are the research agent's (an AI's) own translations; no human translator reviewed them. Relays the Shanghai High People's Court WeChat account; the judgment itself was not inspected.","independence_group":"shanghai-no1-intermediate-court-release"},{"id":"s2","url":"https://news.qq.com/rain/a/20260929A0C6NK00","kind":"news_report","access":"read","language":"zh","translation_note":"Southern Metropolis Daily N Video on Tencent News, read in Chinese on 2026-10-05 (HTTP 200). English renderings in this record are the research agent's (an AI's) own translations; no human translator reviewed them. The reporter cites the Shanghai No. 1 Intermediate People's Court; same court account as s1.","independence_group":"shanghai-no1-intermediate-court-release"},{"id":"s3","url":"https://finance.sina.com.cn/jjxw/2026-09-29/doc-initpatz6144930.shtml","kind":"news_report","access":"read","language":"zh","translation_note":"Legal Daily article carried on Sina Finance, read in the original Chinese on 2026-10-05 (HTTP 200). English renderings in this record are the research agent's (an AI's) own translations; no human translator reviewed them. Same court account with the first-instance court named and a judge's commentary.","independence_group":"shanghai-no1-intermediate-court-release"}],"version":1,"ai_roles":["others_use"],"contexts":["work","privacy","justice"],"unknowns":["Which company and which speech-synthesis product were involved; the court account anonymises both.","When the promotion began and how long the audio was in use.","Whether the company used the voice actor's recordings as training material; the court presumed it because the company did not prove otherwise.","The dates of the filing and of the first-instance judgment.","Where the voice actor lives."],"geography":{"basis":"The case was decided by the Changning District People's Court and the Shanghai No. 1 Intermediate People's Court in China. The reports anonymise the company and the app and do not say where the company is based, where its online promotion ran or where the voice actor lives, so no event or affected-person country is recorded.","court_countries":["CN"],"event_countries":[],"affected_person_countries":[]},"publication":{"basis":"Published as a core case (depicted_or_impersonated): the Shanghai courts found that a company imitated a voice actor's voice with AI-synthesised audio in a promotion without consent and awarded 50,000 yuan. One reporting chain (the court's release, read in three Chinese outlets); the parties are anonymised by the court.","reviewed_on":"2026-10-05"},"ai_involvement":{"basis":"In the court account, the company said the audio was generated by AI it had developed, and both courts found AI-generated voice infringement. The audio imitated the voice actor's voice (depicted_or_impersonated). The company denied using the voice actor's recordings; the appeal court relied on a forensic similarity report and on the company's failure to prove the source of its training material.","status":"supported"},"person_relations":["depicted_or_impersonated"]},"name":"Shanghai: an appeal court upheld a 50,000 yuan award to a voice actor after finding that AI-synthesised audio in a company's online promotion was identifiable as the voice actor's voice","summary":"Chinese outlets reported on 29 September 2026, citing the Shanghai courts, that the Shanghai No. 1 Intermediate People's Court had concluded what it called Shanghai's first voice-rights case arising from AI-synthesised speech. According to the court's account, a voice actor who publishes work on an app learned from a friend in January 2025 that a company appeared to be using the voice actor's voice in an online user-acquisition promotion, judged the audio to be AI-synthesised, had it notarised and sued for 300,000 yuan. The company said the audio was generated by AI it had developed but that the training material could not be confirmed, and denied using the voice actor's voice. A forensic comparison rated about 90 percent of the measured features as fairly or highly similar. The first-instance court awarded 50,000 yuan and both sides appealed. The appeal court held that the company had put an identifiable synthetic voice to commercial use without consent, dismissed the appeals and upheld the award.","incidentDate":"2025-01-01","incidentKind":"single_event","incidentDatePrecision":"month","exposurePattern":"unknown","reportedDate":"2026-09-29","aiSystem":"AI speech synthesis developed by the defendant company (anonymised as Company A in the court account), which the courts found had generated audio imitating the voice actor's voice for an online promotion","aiProduct":"Unidentified voice-cloning tool","severity":"low","verificationStatus":"credible","harmCategories":[],"harmOutcomes":["financial_loss"],"harmOutcomeSummary":"According to the court's account as relayed by Chinese outlets, the Shanghai courts found that AI-synthesised audio used in a company's online promotion was identifiable as a voice actor's voice and had been used without consent, causing economic loss, and awarded 50,000 yuan.","frameworkFacets":[],"causationStatus":"supported","participantUsersAffectedMin":0,"otherPeopleHarmedMin":1,"affectedCountStatus":"exact","affectedCountEvidence":"One person, the voice actor who brought the claim (court account relayed by The Paper, Southern Metropolis Daily and Legal Daily). Exact 1.","victimAgeRange":"adult","jurisdiction":"CN","platformType":"other","outcomeType":"lawsuit_filed","outcomeStatus":"resolved","primarySourceUrl":"https://news.ifeng.com/c/8woTv1MjTRx","primarySourceLabel":"The Paper via ifeng, 29 September 2026: AI took a voice actor's voice, company ordered to pay 50,000 yuan","firstPublishedAt":"2026-10-05T03:16:35.611187+00:00","updatedAt":"2026-10-05T03:16:35.611187+00:00","scopeVersion":"facts-v3","tags":["voice-cloning","voice-rights","voice-actor","court-ruling","shanghai","china","depicted-or-impersonated"]}]}